secwatch.observer — SEC 8-K summary
======================================

Issuer:     Moleculin Biotech, Inc. (MBRX)
CIK:        0001659617
Form:       8-K
Filed at:   2025-10-23T23:59:59+00:00
Accession:  0001437749-25-031574
Event type: other_material
Sentiment:  positive
Materiality: 0.60
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Moleculin announces investigator-initiated Phase 1B/2 study of Annamycin for pancreatic cancer
--------------------------------------------------------------------------------

- Phase 1B/2 single-arm study of Annamycin for third-line advanced pancreatic cancer; investigator-initiated by Atlantic Health.
- Moleculin supplies Annamycin and maintains IND; Dr. Angela Alistar (Atlantic Health) is principal investigator.
- Estimated additional cost to Moleculin ~$1M from 2026 to 2030 for drug supply and testing.
- Preclinical data shows Annamycin targets topoisomerase II, correlated with poor survival in pancreatic cancer.
- Annamycin (naxtarubicin) has Fast Track and Orphan Drug status for AML; Orphan Drug for STS lung mets.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1659617/000143774925031574/0001437749-25-031574-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1659617/000143774925031574/mbrx20251020_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-25-031574

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer